Recurrent infections in a patient with psoriatic arthritis and hypogammaglobulinemia, treated with conventional and biologic disease-modifying anti-rheumatic drugs-a primary or secondary entity?

Clin Rheumatol. 2017 Jul;36(7):1677-1681. doi: 10.1007/s10067-017-3670-1. Epub 2017 May 9.

Abstract

A 54-year-old man with confirmed psoriatic arthritis, treated with conventional and biologic disease-modifying anti-rheumatic drugs, suffered from severe, recurrent respiratory tract infections. He was found to have hypogammaglobulinemia. Further investigations confirmed the diagnosis of common variable immunodeficiency. Introduction of immunoglobulin G replacement therapy allowed for safe and effective treatment of psoriatic arthritis with etanercept and methotrexate. Patients with a history of recurrent infections on disease-modifying anti-rheumatic drugs and hypogammaglobulinemia should be assessed for primary antibody immunodeficiencies, even in adulthood.

Keywords: Biologics; CVID; DMARDS; Infections; Psoriatic arthritis.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Agammaglobulinemia / complications
  • Agammaglobulinemia / drug therapy*
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Psoriatic / complications
  • Arthritis, Psoriatic / drug therapy*
  • Drug Therapy, Combination
  • Etanercept / therapeutic use*
  • Humans
  • Immunoglobulin G / therapeutic use*
  • Male
  • Methotrexate / therapeutic use*
  • Middle Aged
  • Recurrence
  • Respiratory Tract Infections / complications*
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Immunoglobulin G
  • Etanercept
  • Methotrexate